Log in to search using one of your social media accounts:

 

Efficacy of standard dose R-CHOP alternating with R-HDAC followed by autologous hematopoietic cell transplantation as initial therapy of mantle cell lymphoma, a single institution experience

In a retrospective study of 87 patients with mantle cell lymphoma treated with 3 different induction regimens, we show that a modification of the Nordic regimen in which a standard, rather than dose-intense, R-CHOP alternating with high dose cytarabine is a highly effective pre-autologous hematopoietic cell transplantation therapy.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research

Related Links:

A higher risk for a variety of cancers is among the major complications of posttransplantation immunosuppression. In this part of a continuing series on cancers posttransplantation, this review focuses on the hematologic cancers after solid organ transplantation. Posttransplantation lymphoproliferative disorders (PTLDs), which comprise the great majority of hematologic cancers, represent a spectrum of conditions that include, but are not limited to, the Hodgkin and non‐Hodgkin lymphomas. The oncogenic Epstein‐Barr virus is a key pathogenic driver in many PTLD cases, through known and unknown mechanisms. The other hemat...
Source: American Journal of Transplantation - Category: Transplant Surgery Authors: Tags: COMPREHENSIVE REVIEW Source Type: research
This study focuses on the efficacy of pegfilgrastim in PBSC mobilization compared to filgrastim exclusively after novel agent-based induction in a homogeneous group of MM patients. We analyzed 89 patients with MM treated at two transplant centers in Singapore who received novel agent-based induction chemotherapy, PBSC mobilization with vinorelbine / cyclophosphamide, high-dose melphalan conditioning and autologous stem cell rescue. 61 patients were included in the pegfilgrastim group and 28 in the filgrastim group, with a similar median age and disease characteristics. PBSC harvesting was done at a similar median time of 9...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 January 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Henry Chan, Madeline Phillips, Manjula Maganti, Sophia Farooki, Giovanni Piza Rodriguez, Esther Masih-Khan, Christine Chen, Anca Prica, Donna Reece, Rodger Tiedemann, Suzanne Trudel, Vishal Kukreti
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The current standard of care for transplant-eligible myeloma patients is novel agent-based induction followed by high-dose chemotherapy and autologous stem cell rescue. Chemo-mobilization of peripheral blood CD34+ stem cells (PBSC) with pegylated filgrastim (pegfilgrastim), a sustained-duration formulation of filgrastim, has been used as an alternative to filgrastim in several studies involving heterogeneous cohorts of lymphoma and multiple myeloma (MM) patients and shown to be equivalent in PBSC yield and cost-effectiveness.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
Publication date: Available online 24 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Andrea Tendas, Francesco Marchesi, Ombretta Annibali, Debora Saltarelli, Pasquale Niscola, Alessio Pio Perrotti, William Arcese
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion VCR is effective in MCL and iNHL. Although hematologic toxicity can be an issue, this study demonstrates a high response rate to a novel combination and provides an alternative option in transplant-ineligible R/R MCL and iNHL. Micro-Abstract The combination of bortezomib, cladribine, and rituximab is novel and effective in mantle-cell and indolent non-Hodgkin lymphomas.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion The use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ≥ 2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting. Micro-Abstract Patients with relapsed or refractory diffuse large B-cell lymphoma undergoing autologous bone marrow transplantation benefited from consolidative involved-field radiotherapy (IFRT). All patients who underwent consolidative IFRT had improved locoregional co...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Our results suggest that achievement of a CR is imperative in patients with advanced ENKL, and is desirable for any patient for whom auto-SCT is utilized. SMILE-based chemotherapy appeared effective in attaining a CR, and was also an effective salvage regimen. For patients attaining a first CR, auto-SCT should be strongly considered, but should definitely be utilized in patients attaining CR2. For patients with refractory disease, allo-SCT can be considered in a selected group of patients. Micro-Abstract We present a cohort of primarily non-Asian patients with advanced stage and relapsed/refractory ENKL. Our res...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We have read with great interest the paper by Trifilio S. and colleagues1, entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study”. The authors illustrated the result of a retrospective comparative clinical trial of olanzapine-contain ing regimen versus aprepitant or fosaprepitant-containing regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT) with h...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
We have read with great interest the paper by Trifilio and colleagues,1 entitled “Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.” The authors illustrated the result of a retrospective comparative clinical trial of an olanzapine-cont aining regimen versus an aprepitant- or fosaprepitant-containing regimen for the prevention of chemotherapy-induced nausea and vomiting (CINV) among patients affected by multiple myeloma undergoing autologous stem cell transplantation (ASCT...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Study | Transplants